An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Kontrol Technologies Ships BioCloud to New Customer in Hong Kong
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Kontrol Technologies Corp. (OTCQB:KNRLF) has successfully shipped its BioCloud technology to a new customer in Hong Kong, focusing on air quality solutions. Additionally, a testing partner has completed its first purchase of BioCloud technology. Kontrol is set to commence a pilot study of BioCloud for classroom use in the USA, expected to start in early Q2 2022. Notably, the company clarifies that its product does not claim to eliminate or cure COVID-19.
Positive
Successful shipment of BioCloud technology to a new customer in Hong Kong.
First purchase completed by a testing partner for BioCloud technology.
New pilot study on BioCloud technology for classroom use in the USA set to begin in early Q2 2022.
Negative
None.
TORONTO--(BUSINESS WIRE)--
Kontrol Technologies Corp.(NEO:KNR) (OTCQB:KNRLF) (FSE:1K8) (“Kontrol” or the “Company”), a leader in smart building technology, has shipped its BioCloud technology to a new customer in Hong Kong. The customer operates as an integrated national air quality and smart building solutions provider.
In addition, the testing partner described in the Company’s press release dated December 16th, 2021, has completed its first BioCloud technology purchase.
“As organic, internal innovation for early viral detection and continuous monitoring of air quality, we are pleased to continue to grow the BioCloud technology,” says Paul Ghezzi, CEO of Kontrol Technologies.
USA Pilot and Study
Kontrol has received an order for trial of the BioCloud technology for use in classroom applications in the USA from an integrated air quality solutions company. The pilot and study are expected to run for multiple months, with inception anticipated in early Q2 2022.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).
About Kontrol BioCloudTM
Kontrol BioCloud (“BioCloud”) is an operating subsidiary of Canadian public company Kontrol Technologies Corp. The BioCloud technology is a real-time analyzer designed to detect airborne viruses and pathogens. BioCloud is an air quality technology and not a medical device. BioCloud has been designed to operate as a safe space technology by sampling the air quality continuously. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and a silent notification system is created. BioCloud can be applied to any space where individuals gather. Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com
Kontrol Technologies Corp.
Kontrol Technologies Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol provides solutions and services to its customers to improve energy management, monitor continuous emissions and accelerate the sustainability of all buildings.
Additional information about Kontrol Technologies Corp. can be found on its website at www.kontrolcorp.com and by reviewing its profile on SEDAR at www.sedar.com
Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions, and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. Forward-looking information contained in this press releases includes, but is not limited to, the following: future testing to be conducted by Kontrol of its products; the anticipated timing of the USA pilot and study of the BioCloud technology; the future success of any of Kontrol’s products; and customer demand relating to air quality products.
Where Kontrol expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company; that future testing can be conducted as planned; that technology will be as effective as anticipated; that existing relationships and contracts entered into by the Company will continue on the same or similar terms, or at all; that the USA pilot and study relating to the BioCloud technology will be conducted on the terms and timing as currently anticipated; and that demand will continue for air quality products and for the Company’s products in particular.
However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking
statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all; that the Company’s technologies will not prove as effective as expected; that customers and potential customers will not be as accepting of the Company's product and service offerings as expected and/or that demand for such products and services will not continue; that the Company’s test results will not be replicated in the future or that future testing will not be conducted; that the Company will not maintain its existing relationships or contracts on the same terms or at all; that the USA pilot and study relating to the BioCloud technology will not be completed on the timing and terms as currently anticipated, or at all; and government and regulatory factors impacting the energy conservation industry. Kontrol BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).
Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.
